alloantibody
ozogamicin
antiantibody
dorlixizumab
toxin antitoxin
tisotumab
anticorrelate
teplizumab
cergutuzumab
talizumab
autocentromere
antipolyvalent
immunocharacterize
tabalumab
lorvotuzumab
antisynthetase
bispecific
guselkumab
hyperimmunoglobulin
-ab
immunotoxicity
heterophile
caplacizumab
agonistic monoclonal antibody
-o-
antiustekinumab
bivatuzumab
sifalimumab
ixekizumab
polytypic
agglutinin
presentation
-kin-
polyvalent
immunosphere
microlymphocytotoxicity
-ner-
polyantibody
abzyme
heteroclitic
cytoimmunity
soravtansine
tucotuzumab
sonepcizumab
clenoliximab
ibritumomab
antiimmunoglobulin
elotuzumab
immunomolecule